Urinary Tract Diseases Clinical Trial
| NCT number | NCT00239265 |
| Other study ID # | B6171/LCT2 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 3 |
| First received | September 13, 2005 |
| Last updated | October 18, 2007 |
| Verified date | October 2007 |
| Source | Astellas Pharma Inc |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Japan: Ministry of Health, Labor and Welfare |
| Study type | Interventional |
The purpose of this study is to determine whether Tamuslosin is effective in the treatment of lower urinary tract syndrome with female patients.
| Status | Completed |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 20 Years to 90 Years |
| Eligibility |
Inclusion Criteria: - Patients with urination disorder not accompanied by apparent organic or neurologic abnormality(lower urinary tract syndrome: LUTs). Exclusion Criteria: - Patients with urination disorder accompanied by apparent organic or neurologic abnormality, active urinary tract infections, severe cardiovascular, hepatic and/or kidney complications. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Astellas Pharma Inc |
Japan,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02805504 -
Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures
|
Phase 4 | |
| Completed |
NCT00239317 -
Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome
|
Phase 3 |